Skip to Main Content

Paper Details

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
Blood
36
2021
B, B-cell receptor, BCR, BRAF, BTK, Bruton tyrosine kinase, CLL, ERK, KRAS genes, MAP2K1, MAP2K1 mutants, MAPK, MEK, PI3K, chronic lymphocytic leukemia, idelalisib, nonresponder CLL cells, pERK, patients, phosphatidylinositol, phosphatidylinositol 3-kinase, tyrosine
Author NameAffiliation
Svitlana TyekuchevaDana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health
Dimitri LivitzBroad Institute of Massachusetts Institute of Technology and Harvard
Ignaty LeshchinerBroad Institute of Massachusetts Institute of Technology and Harvard
Gad GetzBroad Institute of Massachusetts Institute of Technology and Harvard
Gad GetzCancer Center and Department of Pathology, Massachusetts General Hospital
Gad GetzHarvard Medical School
Gad GetzBroad Institute of Massachusetts Institute of Technology and Harvard
Gad GetzCancer Center and Department of Pathology, Massachusetts General Hospital
Gad GetzHarvard Medical School
  • 1 - 9

Datasets

Release 1.2